Sugi Predict

Sugi Predict / Compounds / SCHEMBL2477903

SCHEMBL2477903

SCHEMBL2477903

CCCNC(=O)c1cc[c]cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ L3MBTL1 Q9Y468 3/20 0.53
▸ NAAA Q02083 2/20 0.50
▸ ALDH1A1 P00352 4/20 0.47
▸ POLB P06746 3/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ DRD2 P14416 1/20 0.46
▸ DRD4 P21917 1/20 0.46
▸ DRD3 P35462 1/20 0.46
▸ CHRNA10 Q9GZZ6 1/20 0.46
▸ CHRNA9 Q9UGM1 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ NAMPT P43490 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MLYCD O95822 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4158767 0.89 SMN1; SMN2 (0.62) KMT2AL3MBTL1NAAAALDH1A1SMN1; SMN2
SCHEMBL4180665 0.87 NAAA (0.68) KMT2AL3MBTL1NAAAALDH1A1SMN1; SMN2
SCHEMBL6716810 0.86 NAAA (0.71) KMT2AL3MBTL1NAAAALDH1A1SMN1; SMN2
SCHEMBL9768658 0.86 NAAA (0.71) KMT2AL3MBTL1NAAAALDH1A1SMN1; SMN2
SCHEMBL9771511 0.86 NAAA (0.71) KMT2AL3MBTL1NAAAALDH1A1SMN1; SMN2
SCHEMBL4169513 0.86 NAAA (0.71) KMT2AL3MBTL1NAAAALDH1A1SMN1; SMN2
SCHEMBL11399405 0.86 NAAA (0.71) KMT2AL3MBTL1NAAAALDH1A1SMN1; SMN2
SCHEMBL11836345 0.86 NAAA (0.71) KMT2AL3MBTL1NAAAALDH1A1SMN1; SMN2
SCHEMBL13918749 0.86 KDM4E (0.70) KDM4EKMT2AL3MBTL1NAAAALDH1A1
SCHEMBL162548 0.84 CA9 (0.46) KMT2AL3MBTL1NAAAALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104744476-A IMIDAZOPYRAZINE Syk INHIBITORS GILEAD CONNECTICUT INC 2015-07-01 — — CN claimed
US-20130267496-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-10-10 — — US claimed
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-12 — — US claimed
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 — — US claimed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 — — EP claimed
EP-2373169-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2011-10-12 — — EP claimed
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-09-02 — — US claimed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 — — WO claimed
WO-2010068257-A1 IMIDAZOPYRAZINE SYK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-06-17 — — WO claimed
EP-2059516-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (publ) (SE) 2009-05-20 — — EP claimed
EP-1768986-A2 FURANOPYRIMIDINES Amgen Inc. (US) 2007-04-04 — — EP claimed
US-20060040961-A1 Furanopyrimidines AMGEN INC. 2006-02-23 — — US claimed
WO-2006004658-A2 FURANOPYRIMIDINES AMGEN INC. (US) 2006-01-12 — — WO claimed
EP-0830349-B1 METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS DU PONT PHARM CO (US) 2000-03-22 — — EP claimed
US-5877312-A Method for preparing alkylating agents for their use for alkylating cyclic ureas DUPONT PHARMACEUTICALS COMPANY (US) 1999-03-02 — — US claimed
EP-0830349-A1 METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1998-03-25 — — EP claimed
US-5637780-A Method for preparing alkylating agents and their use for alkylating cyclic ureas THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-06-10 — — US claimed
EP-0767770-A1 METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-04-16 — — EP claimed
WO-1996039393-A1 METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-12-12 — — WO claimed
WO-1996000708-A1 METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-01-11 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors MTOR, PIKFYVE, RICTOR KDM4E 743/4885KMT2A 1333/4885L3MBTL1 2849/4885
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 KDM4E 1611/4885KMT2A 1035/4885L3MBTL1 3310/4885
US-20060040961-A1 Furanopyrimidines TYMS, IDO1, NFATC1 KDM4E 3284/4885KMT2A 4672/4885L3MBTL1 3937/4885
US-20130267496-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 KDM4E 1611/4885KMT2A 1035/4885L3MBTL1 3310/4885
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 KDM4E 1611/4885KMT2A 1035/4885L3MBTL1 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.